Pfizer Says 2004 Earnings On Target Despite Neurontin Generics
This article was originally published in The Pink Sheet Daily
You may also be interested in...
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
US FDA not planning an advisory committee for Pfizer/BioNTech’s request for authorization in 12-15-year olds at this time, but CDC’s ACIP is likely to weigh how to balance timing of COVID vaccination with administration of other immunizations generally recommended for adolescents.